{"prompt": "['OSTPDL1', '9.6 Toxicity Evaluation Criteria', '43', '10.0OFF TREATMENT AND OFF STUDY CRITERIA', '43', '10.1 Off Treatment Criteria', '43', '10.2 Off Study Criteria', '43', '11.0SAFETY AND ADVERSE EVENT REPORTING REQUIREMENTS', '44', '11.1 Reporting Adverse Experiences and Deaths to St. Jude IRB', '44', '11.2', 'Reporting to St Jude IRB', '46', '11.3 Reporting from St. Jude to Pfizer (Drug Manufacturer)', '46', '11.4 Reporting to St. Jude Regulatory Affairs Office and FDA', '47', '11.5 Recording Adverse Events and Serious Adverse Events', '47', '11.6 Process for Reporting Adverse Events from and to Collaborating Sites 48', '12.0DATA COLLECTION, MONITORING AND CONFIDENTIALITY', '49', '12.1 Data Collection', '49', '12.2 Study Monitoring', '49', '12.3 Confidentiality', '50', '13.OSTATISTICAL CONSIDERATIONS', '50', '13.1 Study Design', '50', '13.2 Secondary Objectives', '52', '13.3 Exploratory Objectives', '52', '13.4 Anticipated Completion Dates', '54', '14.0OBTAINING INFORMED CONSENT', '54', '14.1 Consent Prior to Research Interventions', '54', '14.2 Consent at Enrollment', '54', '14.3 Consent at Age of Majority', '55', '14.4 Consent When English is Not the Primary Language', '55', '14.5 Collection of Collaborating Institution Consent Forms', '55', '15.OREFERENCES', '56', 'APPENDICES', 'Appendix I: Performance Status Scales/Scores', 'Appendix II: New York Heart Association Functional Classification', 'Appendix III:', 'Instructions for Collection and Shipping of Research Blood', 'Samples to NCI', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-3018 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 1 of 60', '1.0 OBJECTIVES', '1.1', 'Primary Objectives', '1.1.1 To estimate the response rate to 4 cycles of avelumab in patients', 'with recurrent or progressive osteosarcoma.', '1.1.2 To estimate the 16-week progression free survival of patients with', 'recurrent or progressive osteosarcoma after treatment with', 'avelumab.', '1.2', 'Secondary Objective', '1.2.1 To describe the toxicities associated with the administration of', 'avelumab in patients with recurrent or progressive osteosarcoma.', '1.3', 'Exploratory Objectives', '1.3.1 To explore factors associated with response in patients treated with', 'avelumab after recurrent or progressive osteosarcoma (e.g. tumor', 'PD-L1 expression).', '1.3.2 To measure parameters of immune activation including subsets of', 'peripheral blood mononuclear cells (PBMCs) and serum markers of', 'immune activation.', '1.3.3 To evaluate the role of T-cells in immune checkpoint blockade via', 'measures of cell proliferation, co-inhibitory receptor expression on', 'CD8 T cells, T cell repertoire, and epigenetic programming.', '1.3.4 To assess the quality of life of patients with recurrent or', 'progressive osteosarcoma undergoing treatment with avelumab,', 'and to explore relationships between clinical factors and patient-', 'reported HRQOL outcomes.', '2.0', 'BACKGROUND AND RATIONALE', '2.1 Background', 'Osteosarcoma is the most common bone tumor in children and', 'adolescents. It is estimated there are approximately 400 new cases of', 'pediatric osteosarcoma diagnosed in the United States each year. 1 Nearly', '70% of children who are treated with osteosarcoma with current therapies', 'that include multimodal chemotherapy with high dose methotrexate,', 'doxorubicin, and cisplatin (MAP) and surgery can be cured from their', 'disease. 2 However, patients who present with metastatic disease or', 'relapse continue to fare poorly with estimated survival rates that do not', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}